v3.26.1
Segment Information (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Segment Reporting, Asset Reconciling Item [Line Items]    
License and other revenue $ 0 $ 15,000
Other R&D expenses:    
General and administrative expenses (19,882) (12,334)
Share-based compensation (10,565) (7,883)
Interest income 5,138 7,890
Interest expense (2,731) (2,877)
Income tax expense (850) (1,397)
Consolidated net loss (79,241) (26,135)
Reportable Segment    
Segment Reporting, Asset Reconciling Item [Line Items]    
License and other revenue 0 15,000
Less:    
Cleminorexton (20,503) (13,666)
Other Orexin program expenses (23,758) (6,427)
LockBody technology program expenses (1,530) (3,418)
Discontinued R&D program expenses 52 (2,917)
Other R&D expenses:    
Personnel expenses (11,714) (6,302)
Research tax incentives 3,630 4,259
Other internal R&D expenses (1,983) (815)
General and administrative expenses (13,402) (8,608)
Share-based compensation (10,565) (7,883)
Interest income 5,138 7,890
Interest expense (2,731) (2,877)
Other segment items (1,025) 1,026
Income tax expense (850) (1,397)
Consolidated net loss $ (79,241) $ (26,135)